Press Release

May 07, 2021
1 min read

FDA approves Tecnis Synergy, Tecnis Synergy Toric II IOLs


Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The FDA approved the Tecnis Synergy and Tecnis Synergy Toric II IOLs for patients with cataracts, according to a press release from Johnson & Johnson Vision.

The company said the presbyopia-correcting IOLs provide better contrast, particularly in low-light environments, and in a company-sponsored study, nine out of 10 patients did not need glasses after surgery.

“The Tecnis Synergy IOL combines the best of extended depth of focus and multifocal technologies to deliver the widest range of continuous vision with the best near vision among leading [presbyopia-correcting] IOLs, without the visual gaps caused by existing trifocal technology,” Rajesh Rajpal, MD, Johnson & Johnson Vision chief medical officer and global head of clinical and medical affairs, said in the release. “Additionally, we’ll offer Tecnis Synergy IOL on our new Toric II platform, when it launches later this year, to give surgeons the ability to address astigmatism at the time of surgery.”

The company expects the Synergy IOLs to be available in the U.S. later this year.

The Tecnis Synergy Toric II IOL also received approval from Health Canada.